Clinical trial
OASIS-6: The Safety and Efficacy of Fondaparinux Versus Control Therapy in…
NCT00064428 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00064428 |
|---|---|
| Title | OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction |
| Official title | An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Versus Control Therapy in a Broad Range of Patients With ST Segment Elevation Acute Myocardial Infarction. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thromboembolism |
| Intervention type | Drug, Other |
| Interventions | fondaparinux - UFH not indicated, Control - UFH not indicated, Fondaparinux - UFH indicated, Control - UFH |
| Enrollment | 12,092 |
| Start date | Aug 1, 2003 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Oct 17, 2003 |
| Last update posted | Sep 23, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: